|
| Press Releases |
|
 |
|
| Friday, May 7, 2021 |
|
|
아방스 클리니컬, 174억 달러 규모 시장 수요를 충족하는 유전 기술 임상 시험 서비스 확대 |
| 호주의 바이오테크 임상수탁기관(CRO) 선두주자이자 프로스트&설리번(Frost & Sullivan)이 수여하는 아시아-태평양 CRO 마켓 리더십 어워드(Asia-Pacific CRO Market Leadership Award)를 수상한 바 있는 아방스 클리니컬은 2023년까지 174억 달러 규모로 증가할 것으로 예상되는 글로벌 수요를 충족할 수 있도록 유전 기술 임상 시험 서비스를 확대해 왔다. more info >> |
|
|
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand |
| The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. more info >> |
|
| Friday, April 23, 2021 |
|
|
Avance Clinical社がOracle Health Sciences Connectで「Decentralized Trials - No Going Back」と題した講演に招待されました |
| オーストラリアを代表するバイオテクノロジー企業向けCROであり、フロスト＆サリバン社のアジア太平洋CROマーケット・リーダーシップ・アワードを受賞したアヴァンス・クリニカルは、オラクル・ヘルス・サイエンス・コネクト・カンファレンスに招待され、分散型臨床試験の未来について発表しました。 more info >> |
|
|
아방스 클리니컬, 오라클 헬스 사이언스 커넥트에 초청되어 "분산형 실험 - 이전으로 돌아갈 수 없는 획기적 발전" 발표 |
| 호주의 바이오테크 임상수탁기관(CRO)선두주자이자 프로스트&설리번(Frost & Sullivan)이 수여하는 아시아태평양 CRO 마켓 리더십 어워드(Asia-Pacific CRO Market Leadership Award)를 수상한 바 있는 아방스 클리니컬은 오라클 헬스 사이언스 커넥트 컨퍼런스에 초청받아 분산형 임상실험(decentralized clinical trials, DCT)의 미래에 대해 발표했다. more info >> |
|
| Thursday, April 22, 2021 |
|
|
Avance Clinical受邀發表“分散試驗–不再回頭” 適用於Oracle Health Sciences Connect |
| 澳大利亞領先的生物技術CRO和Frost＆Sullivan亞太CRO市場領導獎獲得者Avance Clinical已應邀在Oracle Health Sciences Connect會議上介紹了分散臨床試驗的未來。 more info >> |
|
|
Avance Clinical受邀发表“分散试验–不再回头” 适用于Oracle Health Sciences Connect |
| 澳大利亚领先的生物技术CRO和Frost＆Sullivan亚太CRO市场领导奖获得者Avance Clinical已应邀在Oracle Health Sciences Connect会议上介绍了分散临床试验的未来。 more info >> |
|
|
Avance Clinical Invited to Present "Decentralized Trials - No Going Back" for Oracle Health Sciences Connect |
| The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference. more info >> |
|
| Friday, March 12, 2021 |
|
|
Avance臨床客戶Atossa Therapeutics宣布了第一階段臨床研究的最終結果，該研究表明針對COVID-19研發的AT-301鼻噴霧劑的安全性和耐受性 |
澳大利亞領先的生物技術CRO和Frost＆Sullivan亞太CRO市場領導獎獲得者Avance Clinical祝賀Atossa Therapeutics宣布了他們為COVID-19開發的AT-301鼻噴霧劑的第一階段最終結果。
more info >> |
|
|
Avance临床客户Atossa Therapeutics宣布了第一阶段临床研究的最终结果，该研究表明针对COVID-19研发的AT-301鼻喷雾剂的安全性和耐受性 |
| more info >> |
|
|
Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19 |
| The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
侨雄国际宣布委任段玉聪院士为人工智能实验室首席科学家
Nov 5, 2024 19:25 HKT/SGT
|
|
|
华邦科技正式更名为「亨利加集团有限公司」
Nov 5, 2024 19:15 HKT/SGT
|
|
|
華邦科技正式更名為「亨利加集團有限公司」
Nov 5, 2024 19:11 HKT/SGT
|
|
|
僑雄國際宣佈委任段玉聰院士為人工智能實驗室首席科學家
Nov 5, 2024 19:00 HKT/SGT
|
|
|
ALMAC to open mid-November
Nov 5, 2024 18:46 HKT/SGT
|
|
|
Champion REIT Recognised as 'GRESB Global Listed Sector Leader'
Nov 5, 2024 18:11 HKT/SGT
|
|
|
富士通、東証の株式売買システム「arrowhead4.0」を運用開始
Nov 5, 2024 18:00: JST
|
|
|
冠君产业信托获GRESB评为「全球业界领导者（上市企业）」
Nov 5, 2024 17:41 HKT/SGT
|
|
|
冠君產業信託獲GRESB評為「全球業界領導者（上市企業）」
Nov 5, 2024 17:14 HKT/SGT
|
|
|
Victory and world title for TOYOTA GAZOO Racing
Nov 5, 2024 17:59 JST
|
|
|
Tokyo Stock Exchange and Fujitsu announce renewal of cash equity trading system 'arrowhead4.0'
Nov 5, 2024 17:13 JST
|
|
|
Mitsubishi Heavy Industries Continues Order Intake, Revenue, and Profit Growth in Strong First Half, Raises Full-Year Order Intake Guidance
Nov 5, 2024 14:37 JST
|
|
|
Interroyal Engineering PCL (SET: IROYAL) Posts Strong Showing on First Trading Day
Nov 5, 2024 13:00 HKT/SGT
|
|
|
華泰證券入圍「跨境理財通」試點 服務大灣區多元化財富管理需求
Nov 5, 2024 11:50 HKT/SGT
|
|
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 5, 2024 11:35 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
